Shiro Ikegawa Selected Research

Torrance Type Platyspondylic Lethal Skeletal Dysplasia

12/2015	Endoplasmic reticulum stress-mediated apoptosis contributes to a skeletal dysplasia resembling platyspondylic lethal skeletal dysplasia, Torrance type, in a novel Col2a1 mutant mouse line.
6/2011	ENU-induced missense mutation in the C-propeptide coding region of Col2a1 creates a mouse model of platyspondylic lethal skeletal dysplasia, Torrance type.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shiro Ikegawa Research Topics

Disease

15	Osteoarthritis 07/2021 - 02/2005
6	Osteochondrodysplasias (Spondyloepiphyseal Dysplasia) 01/2016 - 01/2003
5	Osteoporosis 11/2016 - 10/2007
4	Knee Osteoarthritis 09/2009 - 01/2006
3	Inflammation (Inflammations) 07/2021 - 03/2009
3	Intervertebral Disc Displacement (Herniated Disc) 01/2018 - 12/2007
3	Intervertebral Disc Degeneration 07/2017 - 11/2013
3	Retinal Degeneration 01/2016 - 10/2011
3	Joint Diseases (Joint Disease) 08/2015 - 01/2008
3	Diastrophic dysplasia 04/2010 - 06/2006
3	Metabolic Bone Diseases (Osteopenia) 10/2009 - 01/2008
3	Myocardial Infarction 03/2009 - 01/2006
2	Heterotopic Ossification (Ectopic Ossification) 10/2022 - 01/2002
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/2022 - 01/2022
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 04/2013
2	Pain (Aches) 07/2021 - 01/2002
2	Desbuquois syndrome 01/2020 - 01/2017
2	Neoplasms (Cancer) 06/2019 - 07/2002
2	Scoliosis 10/2017 - 06/2011
2	Joint Instability (Joint Laxity) 01/2017 - 12/2011
2	of childhood progressive pseudorheumatoid Arthropathy 01/2016 - 01/2016
2	Torrance Type Platyspondylic Lethal Skeletal Dysplasia 12/2015 - 06/2011
2	Pyle disease 04/2015 - 01/2007
2	Retinitis Pigmentosa (Pigmentary Retinopathy) 10/2013 - 10/2011
2	Rheumatoid Arthritis 06/2010 - 01/2008
2	Intervertebral disc disease 01/2008 - 06/2005
2	Cartilage-hair hypoplasia 11/2007 - 12/2003
2	Camurati-Engelmann Syndrome (Progressive Diaphyseal Dysplasia) 10/2007 - 01/2002
2	Hip Osteoarthritis (Coxarthrosis) 04/2007 - 07/2002
2	Pseudoachondroplasia 08/2004 - 01/2003
2	Retinoblastoma (Glioblastoma, Retinal) 07/2002 - 05/2002
1	Osteonecrosis (Kienbock's Disease) 01/2022
1	Congenital Abnormalities (Deformity) 01/2022
1	Autosomal Recessive 7 Osteopetrosis 01/2022
1	Hypophosphatemic Rickets 01/2022
1	Hypersensitivity (Allergy) 07/2021
1	Developmental Bone Diseases (Bone Dysplasia) 06/2021
1	Dysosteosclerosis 04/2021
1	Osteophyte 01/2021
1	Synovitis 01/2021
1	Prostatic Neoplasms (Prostate Cancer) 01/2020
1	Osteomalacia 06/2019
1	Paraneoplastic Syndromes (Paraneoplastic Syndrome) 06/2019
1	Rickets (Rachitis) 06/2019
1	Osteoporotic Fractures 01/2019
1	Arthritis (Polyarthritis) 01/2016
1	type 1 Stickler syndrome 01/2016
1	Osteogenesis Imperfecta (Lobstein Disease) 01/2016
1	AIDS-Related Complex (ARC) 01/2016
1	Rare Diseases (Rare Disease) 01/2016
1	Myopia 01/2016
1	Cataract (Cataracts) 01/2016

Drug/Important Bio-Agent (IBA)

14	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2002
6	Collagen Type II (Type II Collagen)IBA 01/2016 - 08/2003
4	Aspartic Acid (Aspartate)FDA Link 02/2011 - 02/2005
3	Biological ProductsIBA 05/2022 - 01/2008
3	GlycosaminoglycansIBA 01/2020 - 04/2013
3	Transcription Factors (Transcription Factor)IBA 01/2020 - 05/2002
3	EnzymesIBA 01/2017 - 04/2013
3	CollagenIBA 01/2016 - 07/2002
3	Proteoglycans (Proteoglycan)IBA 04/2013 - 06/2006
3	Sulfate TransportersIBA 04/2010 - 06/2006
3	Transforming Growth Factor beta (TGF-beta)IBA 06/2005 - 01/2002
2	Phosphates (Orthophosphate)IBA 01/2022 - 06/2019
2	Protein Isoforms (Isoforms)IBA 06/2021 - 08/2008
2	Tuberculin (PPD)IBA 01/2016 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 10/2013 - 04/2011
2	ThrombospondinsIBA 02/2013 - 01/2008
2	Alkaline PhosphataseIBA 02/2011 - 01/2002
2	Pharmaceutical PreparationsIBA 06/2008 - 02/2002
2	5' Untranslated Regions (5' UTR)IBA 05/2008 - 04/2007
2	Factor V (Coagulation Factor V)IBA 01/2008 - 10/2007
2	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2008 - 10/2004
2	Transforming Growth Factor-beta Type II ReceptorIBA 04/2007 - 08/2006
2	Transforming Growth Factor-beta Type I ReceptorIBA 04/2007 - 08/2006
2	von Willebrand FactorIBA 07/2005 - 11/2004
2	Cartilage Oligomeric Matrix ProteinIBA 08/2004 - 01/2003
1	Vitamin A (Retinol)FDA LinkGeneric 10/2022
1	SteroidsIBA 01/2022
1	andrographolideIBA 07/2021
1	Type II Tumor Necrosis Factor ReceptorsIBA 07/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2021
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 07/2021
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2021
1	CationsIBA 01/2021
1	Capsaicin (Zostrix)FDA Link 01/2021
1	Fibroblast Growth Factor-23IBA 06/2019
1	Indicators and Reagents (Reagents)IBA 01/2019
1	LipidsIBA 01/2018
1	MicroRNAs (MicroRNA)IBA 10/2017
1	Dichlorodiphenyldichloroethane (DDD)IBA 07/2017
1	chondroitin sulfate N-acetylgalactosaminyltransferase-1IBA 01/2017
1	Genetic Markers (Genetic Marker)IBA 11/2016
1	Leucine (L-Leucine)FDA Link 01/2016
1	alpha2 Subunit Collagen Type IIBA 01/2016
1	human CCN6 proteinIBA 01/2016
1	BiglycanIBA 01/2016

Therapy/Procedure

1	Aftercare (After-Treatment) 07/2021
1	Therapeutics 01/2021
1	Intra-Articular Injections 01/2021